MetaSight

Delivering multi-OMIC testing purposefully designed

for population scale use

OUR APPROACH

MetaSight pioneers the development of accurate, affordable, and accessible disease diagnostics and monitoring through advanced blood testing, designed for high-volume population-scale screening.

  • We utilize a robust discovery platform that integrates three key components: Proprietary high throughput mass-spectrometry multi-OMICs technology, population-scale serum samples collection, and continuous access to electronic health records.
  • This integrated discovery platform underpins our multi-disease diagnostic clinical study, the Israel Multi-OMICS Screening Trial, which includes more than half a million participants.
  • Through this initiative, MetaSight has established the world’s largest blood molecular database, driving innovation and precision in disease diagnostics and monitoring.

Our diagnostics discovery platform delivers robust, reproducible signatures that have been validated across diverse clinical settings and global regions:

  • Derived from hundreds of thousands of patients across hundreds of clinics, reflecting real-world diagnostic screening programs.
  • Incorporate patients with diverse, matched co-morbidities, ensuring broad applicability.
  • All samples are collected prior to diagnosis, preventing artifacts introduced by treatment or lifestyle changes.
Our Pipeline